Jill Herendeen, Pharm.D., is Silverback’s vice president of regulatory affairs. She has more than 15 years of experience in drug development within the biotechnology and pharmaceutical industry, working on programs in early-phase development through mid- to late-stage development, including global dossiers for initial marketing authorization and life-cycle management. Prior to joining Silverback, Jill held regulatory positions at Amgen, ZymoGenetics/Bristol Myers Squibb, and Pharmacyclics. Jill has developed a track record of strong partnerships with global health authorities across the US, EU, and ROW regions. Jill is an experienced regulatory leader in the successful development and implementation of global regulatory strategies, leading to approval of oncology therapeutics to treat serious conditions of unmet need. Jill received her Pharm.D. from University of Washington and a B.S. in Biology from Gonzaga University. She completed a pharmacy practice residency at University of North Carolina (UNC) at Chapel Hill and a drug development fellowship specializing in oncology at UNC Chapel Hill and GlaxoSmithKline.